Background {#Sec1}
==========

The term POEMS is derived from the primary features of the disease: polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes \[[@CR1]\]. POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell disorders such as osteosclerotic myeloma (OSM) or Castleman's disease (CD) \[[@CR2],[@CR3]\]. Polyneuropathy is a typical symptom of this syndrome, and can be fatal if it is not improved with treatments \[[@CR4]-[@CR6]\]. Other important clinical features, which are not included in the POEMS acronym, include papilledema, thrombocytosis/erythrocytosis, elevated vascular endothelial growth factor (VEGF) levels, and extravascular volume overload such as peripheral edema, ascites, pleural effusion, and pericardial effusion \[[@CR6]-[@CR9]\]. Since there is no single diagnostic test for the diagnosis of POEMS syndrome, the diagnosis is typically based on the presence of polyneuropathy associated with monoclonal plasma cell disorders presenting with the distinct symptoms described above. Currently, the Mayo Clinic POEMS diagnostic criteria are generally accepted and widely used \[[@CR3],[@CR6],[@CR10]\].

Previous studies have shown that radiotherapy and chemotherapy are effective treatments for solitary and multiple lesions, respectively \[[@CR10]-[@CR13]\]. Sometimes, surgery can be an option for patients with cranial vault plasmacytoma \[[@CR14]\]. However, the role of radiotherapy in patients with multiple lesions remains unclear, and the treatment outcomes vary according to the underlying plasma cell disorders \[[@CR15]\].

In the current study, we analyzed the effects of various treatments, including radiotherapy, chemotherapy, or combined treatment on the symptoms and disease control in patients with POEMS syndrome.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We retrospectively reviewed the medical records of 33 patients who met diagnostic criteria for POEMS syndrome, as proposed by the Mayo clinic \[[@CR7]\] and treated at the Yonsei University Health System in Seoul, Korea, in the period between March of 2000 and February of 2013. Patients were diagnosed with POEMS syndrome if they met the two mandatory major criteria (polyneuropathy and monoclonal plasma cell-proliferative disorder), at least one of the other major criteria (CD, sclerotic bone lesion, and VEGF elevation), and at least one of the minor criteria (organomegaly, extravascular volume overload, endocrinopathy, skin changes, papilledema, and thrombocytosis/polycythemia). Plasma cell-proliferative disorders were classified into four groups: OSM, CD, OSM with CD, and VEGF elevation without gross lesions. All patients underwent pretreatment evaluation including a complete blood cell count (CBC), blood chemistry analysis, serum and urine electrophoresis and immunofixation to detect M-protein, whole body bone scan (WBBS), positron emission tomography/computed tomography, and bone marrow biopsies from the bilateral iliac bones; in patients treated after 2007, the serum VEGF levels were measured. To identify the gross aggregation of plasma cells in the bone marrow, immunohistochemistry for syndecan-1 (CD138) was performed.

The study was approved by the Institutional Review Board of the Yonsei University Health System.

Follow-up {#Sec4}
---------

The treatment responses were evaluated on the basis of several outcomes, including subjective symptom improvements reported by the patients or treating physicians, and physical examination findings. Furthermore, a nerve conduction velocity test, serum immunoglobulin (Ig)A/G/M, lambda/kappa chain, and imaging studies were also performed to evaluate the treatment responses. Clinical responses were evaluated by assessing improvements in symptoms associated with POEMS syndrome, such as polyneuropathy, skin changes, pulmonary edema, and extravascular volume overload. Clinical response was categorized as improved, mixed, stable, or progressed according to previous study \[[@CR12]\], and only the patients who experienced clinical symptom improvement were considered as responder. Hematologic responses were defined using the criteria from a previous study \[[@CR11]\]: complete hematologic response (CR~H~), no abnormal plasma cell aggregation in the bone marrow and negative immunofixation in the serum and urine; very good partial response (VGPR~H~), a 90% reduction in the M-protein levels or positive immunofixation, as long as M-protein level was at least 0.5 g/dL at baseline; and partial hematologic response (PR~H~), a 50% reduction in serum M-protein levels. Other cases were defined as no hematologic response (NR~H~). Follow-up monitoring included CBC, blood chemistry analyses, serum and urine assays to detect M-protein, and imaging studies of the treated areas. Progression was defined as any event as follows; increase in the M-component in the serum or urine, aggravation of symptoms associated with POEMS syndromes, or progression of disease observed upon imaging studies.

Statistical analysis {#Sec5}
--------------------

Progression-free survival (PFS) and overall survival (OS) were quantified from the date of diagnosis to the event of interest. Statistical analyses were conducted using SPSS version 20 (SPSS Inc., Chicago, IL). A *p* value \<0.05 was considered statistically significant. Differences in clinical features and response rates between patient groups were analyzed using the Pearson\'s Chi-squared test. Patient survival was evaluated using Kaplan-Meier survival curves, and the log-rank test was used to compare survival rates between groups. Prognostic factors for survival were analyzed by univariate analyses using the log-rank test.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

The clinical and laboratory characteristics of the patients at the time of diagnosis are summarized in Table [1](#Tab1){ref-type="table"}. All patients presented with a sensorimotor polyneuropathy in nerve conduction test. Sixteen (48%) patients had a poor performance status of Eastern Cooperative Oncology Group performance score (3), owing to the presence of peripheral polyneuropathy. All patients presented with more than four features included in the Mayo Clinic diagnostic criteria, and 42% of patients presented with more than seven features. Thirty (91%), one (3%), and two (6%) patients presented with lambda, kappa, and both light chains, respectively. The median frequency of plasma cells in the bone marrow was 3% (range, 0-18%).Table 1**Patient clinicodemographic characteristics and laboratory findingsCharacteristicAll (n = 33)RT (** ***n*** **= 13)Non-RT (** ***n*** **= 20)No. of patients (%)No. of patients (%)No. of patients (%)*p*** **value** ^**\***^Median age, year (range)45 (25--68)51 (25--68)45 (28--63)0.592Gender Male24 (73)12 (92)12 (60)0.056 Female9 (27)1 (8)8 (40)ECOG performance status 16 (18)2 (15)4 (20)0.451 211 (33)6 (46)5 (25) 316 (48)5 (39)11 (55)Number of POEMS features ≤7 features19 (58)7 (54)12 (60)1.000 \>7 features14 (42)6 (46)8 (40)Type of M-protein IgG17 (52)8 (62)9 (45)0.305 IgA13 (39)5 (38)8 (40) IgG and IgA3 (9)0 (0)3 (15)Type of plasma cell-proliferative disorder OSM13 (39)8 (62)5 (25)0.067 CD4 (12)0 (0)4 (20)0.136 OSM + CD10 (30)5 (38)5 (25)0.461 VEGF elevation without gross lesion6 (18)0 (0)6 (30)0.060Plasma cell component in bone marrow ≤5%20 (61)8 (62)12 (60)1.000 \>5%13 (39)5 (38)8 (40)Abnormal clonal plasma cells in bone marrow Absent28 (85)13 (100)15 (75)0.131 Present5 (15)0 (0)5 (25)Laboratory findings ESR \>20 mm/h16 (48)5 (38)11 (55)1.000 Hemoglobin \<11 g/dL2 (6)0 (0)2 (10)0.508 Hemoglobin \>16 g/dL5 (15)4 (31)1 (5)0.066 Platelets \>450 x 10^3^/μL11 (33)2 (15)9 (45)0.128 Creatinine clearance \<60 mL/min5 (15)0 (0)5 (25)0.131RT, radiotherapy; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; OSM, osteosclerotic myeloma; CD, Castleman's disease; VEGF, vascular endothelial growth factor; ESR, erythrocyte sedimentation rate.^\*^The *p* value was calculated by the Pearson's Chi-squared test between RT and non-RT.

The features of POEMS syndrome according to the administration of radiotherapy are summarized in Table [2](#Tab2){ref-type="table"}. Peripheral polyneuropathy, one of the major diagnostic criteria, was observed in all patients. All patients presented with polyneuropathy in the lower extremities, and 10 patients also had polyneuropathy in the upper extremities. For the 10 patients with polyneuropathy in both the upper and lower extremities, the symptoms had presented in the lower extremities first. Elevated protein levels in the cerebrospinal fluid were observed in 18 patients among 20 patients with available data (90%). The frequencies of extravascular volume overload including ascites (*p* = 0.009), and pleural effusion (*p* = 0.004) and pericardial effusion (*p* = 0.027) were significantly lower in patients who underwent radiotherapy. The frequency of patients presenting bone lesions was significantly higher in patients treated with radiotherapy compared to all other patients (100% versus 50%, *p* = 0.008).Table 2**POEMS features of the study patientsCharacteristicAll (n = 33)RT (** ***n*** **= 13)Non-RT (** ***n*** **= 20)*p*** **value** **\*No. of patients (%)No. of patients (%)No. of patients (%)**Polyneuropathy Peripheral neuropathy33 (100)13 (100)20 (100)N/A CSF protein \>50 mg/dL18/20 (90)5/5 (100)13/15 (87)1.00Organomegaly Hepatomegaly16 (48)6 (46)10 (50)1.000 Splenomegaly18 (55)7 (54)11 (55)0.614 Lymphadenopathy15 (45)5 (38)10 (50)0.722Endocrinopathy Diabetes mellitus6 (18)3 (23)3 (15)0.659 Hypothyroidism15 (45)3 (23)12 (60)0.072 Gonadal axis abnormality10 (30)3 (23)7 (35)0.701 Adrenal axis abnormality8 (24)5 (38)3 (15)0.213 Hyperparathyroidism0 (0)0 (0)0 (0)N/ASkin changes Hyper-pigmentation25 (76)11 (85)14 (70)0.431 Acrocyanosis and plethora1 (3)0 (0)1 (5)1.000 Hemangioma/telangiectasia0 (0)0 (0)0 (0)N/A Hypertrichosis16 (48)6 (46)10 (50)1.000Extravascular volume overload Peripheral edema19 (58)6 (46)13 (65)0.472 Ascites12 (36)1 (8)11 (55)0.009 Pleural effusion13 (39)1 (8)12 (60)0.004 Pericardial effusion7 (21)0 (0)7 (35)0.027Types of bone lesion Osteolytic4 (12)2 (15)2 (10)0.488 Osteosclerotic14 (42)7 (54)7 (35) Mixed5 (15)4 (31)1 (5)No. of bone lesion None10 (30)0 (0)10 (50)0.008 Solitary11 (33)7 (54)4 (20) Multiple12 (36)6 (46)6 (30)RT, radiotherapy; CSF, cerebrospinal fluid; N/A, not applicable.^\*^The *p* value was calculated by the Pearson's Chi-squared test between RT and non-RT.

Radiotherapy was administered to 13 patients (39%) presenting with OSM with or without CD, and non of these patients presented with abnormal clonal plasma cells in the bone marrow. Almost patients (n = 10) treated with radiation doses of 40 Gy or more. Twenty-five patients (76%) were treated with chemotherapy. Four patients did not undergo definitive radiotherapy or chemotherapy due to low performance status or patients' refusal; three of these patients were instead treated with prednisolone or dexamethasone alone, while one patient received prednisolone and intravenous immunoglobulin. Nine patients received both radiotherapy and chemotherapy. Detailed treatment features are summarized in Table [3](#Tab3){ref-type="table"}.Table 3**TreatmentsVariableNo. of case (%)MedianRange**Radiotherapy13 (100)Irradiated site Spine6 (46)N/AN/A Pelvic bone5 (38)N/AN/A Lymph nodes2 (15)N/AN/ANo. of irradiated bone lesions Single7 (54)11 Multiple6 (46)42-6Total dose, Gy13 (100)4530-50Fraction size, Gy13 (100)21.8-3Chemotherapy25 (100) Melphalan and prednisolone4 (16)N/AN/A Vincristine, doxorubicin, and dexamethasone2 (8)N/AN/A High-dose chemotherapy with APBSCT15 (60)N/AN/A Others4 (16)N/AN/AN/A, non applicable; APBSCT, autologous peripheral blood stem cell transplantation.

Treatment responses {#Sec8}
-------------------

The various treatments and the responses according to the underlying disease are summarized in Figure [1](#Fig1){ref-type="fig"}. Among the 23 patients presenting with OSM (with or without CD), six and 14 patients were initially treated with radiotherapy and chemotherapy, respectively. The proportions of patients showing improved clinical symptoms after the initial treatment were 67% and 50% in the radiotherapy and chemotherapy groups, respectively. Out of the 14 patients who initially received chemotherapy, seven patients subsequently received radiotherapy due to poor clinical responses to chemotherapy alone. Among these patients, three patients presented with a single bone lesion, whereas four patients had multiple bone lesions more than three. After salvage radiotherapy, six of these seven patients showed clinical response.Figure 1**Clinical and hematologic responses of initial and salvage treatments according to underlying disease types of POEMS syndrome.** OSM, osteosclerotic myeloma; CD, Castleman's disease; VEGFe, vascular endothelial growth factor elevation without gross lesion; Ig, immunoglobulin; CRR, clinical response rate; HRR, hematologic response rate. \*In these patients, the clinical symptoms were not improved by chemotherapy. ^⁑^In these patients, the serum M-protein persisted after chemotherapy. ^§^In these patients, the clinical symptoms and hematologic status were not improved by chemotherapy.

Six patients with multiple lesions underwent radiotherapy due to poor performance status deemed inadequate for chemotherapy (n = 2), and poor clinical symptom response after chemotherapy (n = 4). Out of these six patients, the clinical symptoms were improved in five patients after radiotherapy, although the serum M-protein levels were reduced in only one patient by radiotherapy. The 10 patients with CD or VEGF elevation without gross lesions were treated with chemotherapy (n = 9) or prednisolone and immunoglobulin (n = 1).

Overall, 23 patients (70%) showed improved clinical symptoms after treatments. The clinical response rates for the patients treated with radiotherapy alone, chemotherapy alone, and chemoradiotherapy were 75%, 69%, and 89%, respectively, and these were not statistically different according to the treatments (*p* = 0.528). In addition, two (50%), 11 (69%), and six patients (67%) showed hematologic response after radiotherapy alone, chemotherapy alone, and chemoradiotherapy, respectively. No significant differences were observed between the treatment groups in hematologic response rate (*p* = 0.777). OSM patients with or without CD showed better clinical and hematologic responses compared with patients with CD only or VEGF elevation without gross lesions (Table [4](#Tab4){ref-type="table"}).Table 4**Treatment responses according to treatment modality and type of plasma cell-proliferative disorderFeatureNo. of Pts,Clinical responseHematologic responseNo. of patients (%)No. of patients (%)ImprovedMixedStableProgressionCR** ~**H**~**VGPR** ~**H**~**PR** ~**H**~**NR** ~**H**~RT43 (75)0 (0)1 (25)0 (0)1 (25)1 (25)0 (0)2 (50)CHT1611 (69)1 (6)2 (13)2 (13)5 (31)2 (13)4 (25)5 (31)RT + CHT98 (89)0 (0)0 (0)1 (11)4 (44)1 (11)1 (11)3 (33)Steroid or Ig41 (25)1 (25)1 (25)1 (25)0 (0)0 (0)0 (0)4 (100)OSM1311 (84)0 (0)1 (8)1 (8)6 (46)1 (8)3 (23)3 (23)CD42 (50)0 (0)1 (25)1 (25)0 (0)1 (25)2 (50)1 (25)OSM + CD107 (70)1 (10)1 (10)1 (10)3 (30)2 (20)0 (0)5 (50)VEGFe63 (50)1 (17)1 (17)1 (17)1 (17)0 (0)0 (0)5 (83)Pts, patients; CR, complete response; VGPR, very good partial response; PR, partial response; NR, no response; RT, radiotherapy; CHT, chemotherapy; Ig, immunoglobulin; OSM, osteosclerotic myeloma; CD, Castleman's disease; VEGFe, vascular endothelial growth factor elevation without growth lesion.

Survivals and prognostic factors {#Sec9}
--------------------------------

The median follow-up was 40 months for the surviving patients. The median PFS for all patients was 51 months with the 5-year PFS rate being 43% (Figure [2](#Fig2){ref-type="fig"}A). The 5-year PFS rate was better in patients treated with chemoradiotherapy (76%) compared to patients treated with radiotherapy alone (33%) or chemotherapy alone (28%). However, this result was not statistically significant (*p* = 0.324). The median OS for all patients was 65 months, with the 5-year OS rate being 57% (Figure [2](#Fig2){ref-type="fig"}B). The 5-year OS rate was worse in patients treated with radiotherapy alone (25%) than patients treated with chemotherapy alone (68%) or chemoradiotherapy (69%). This result did not reach statistic significance (*p* = 0.094). During the follow-up period, 13 patients died, including two, five, four, one, and one from treatment-related causes after chemotherapy, renal failure, pneumonia, coronary artery occlusive disease, and cerebral hemorrhage after falling down, respectively.Figure 2**Kaplan-Meier plot of (A) progression-free survival and (B) overall survival for all patients (n = 33), and patients treated with radiotherapy alone (n = 4), chemotherapy alone (n = 16), and chemoradiotherapy (n = 9).** RT, radiotherapy; CHT, chemotherapy.

The results of the univariate analyses for PFS and OS are shown in Table [5](#Tab5){ref-type="table"}. In the univariate analyses, the use of chemotherapy was found to be a significant prognostic factor for PFS (3-year PFS, 71.5% versus 17.5%, *p* = 0.007) and OS (3-year OS, 74.1% versus 18.2%, *p* = 0.020). Moreover, VEGF elevation without gross lesions was found to be associated with a worse PFS (3-year PFS, 25.0% versus 66%, *p* = 0.035) and OS (3-year OS, 16.7% versus 74.1%, *p* = 0.008) compared with the other subtypes of POEMS syndrome.Table 5**Univariate prognostic factor analysisFactorNo. of case3-year PFS (%)*p*** **value** ^**\***^**3-year OS (%)*p*** **value** ^**\***^Age \>50 years (vs. ≤50 years)13/2053.3/62.40.93156.4/66.00.259Radiotherapy (Y/N)13/2064.8/56.70.31066.6/59.40.782Chemotherapy (Y/N)25/871.5/17.50.00774.1/18.20.020HD Chemotherapy with ABSCT (vs. SD chemotherapy)15/1080.8/58.30.29178.8/66.70.253IgG M-protein subtype (vs. other subtypes)17/1654.4/65.60.71961.1/65.80.775VEGF elevation without gross lesion (vs. other subtypes)6/2725.0/66.00.03516.7/74.10.008BM plasma cells more than 5% (vs. ≤5%)13/2061.4/59.50.77160.6/62.50.821The presence of abnormal clonal plasma cells in BM (Y/N)5/2860.0/60.80.24980.0/60.40.552Extravascular volume overload except peripheral edema (Y/N)16/1749.2/70.00.15553.5/71.10.212Number of POEMS features \>7 (vs. ≤7)14/1946.4/67.70.22045.9/74.20.127Multiple bone lesions (vs. single bone lesion)12/1162.3/66.30.74277.9/70.70.906PFS, progression free survival; OS, overall survival; ABSCT, autologous peripheral blood stem cell transplantation; SD, standard dose; Ig, immunoglobulin; VEGF, vascular endothelial growth factor; BM, bone marrow.^\*^Log-rank test.

Discussion {#Sec10}
==========

POEMS syndrome is a rare paraneoplastic syndrome resulting from underlying plasma cell proliferative diseases including OSM, CD, and VEGF elevation without gross lesion. Although a large case series of the disease was reported in the United States over a decade ago \[[@CR6]\], the underlying pathogenesis and optimal treatment for POEMS syndrome remains unclear, partly due to the lack of randomized trials on the topic \[[@CR7],[@CR16]\]. The results of the present study suggest that local radiotherapy could achieve durable clinical and hematologic responses in selected patients.

Osteosclerotic myeloma is characterized by osteosclerotic bone lesions caused by plasmacytoma or associated with POEMS syndrome. On the other hand, multiple myeloma is typically associated with osteolytic bone lesions \[[@CR17]\], while bone lesions in cases of polyneuropathy are often osteosclerotic or mixed osteosclerotic and osteolytic \[[@CR5],[@CR6]\]. Several studies have shown that OSM with a low burden of clonal plasma cells can be effectively treated with local radiotherapy \[[@CR5],[@CR6],[@CR12],[@CR18]-[@CR21]\]. Accordingly, in our study, we found that radiotherapy or radiotherapy plus chemotherapy produced a good clinical response of 89% and a hematologic response of 67%. Although the optimal dose of radiation for OSM has not been thoroughly investigated, moderate doses of over 40 Gy may be appropriate, as in the case of solitary plasmacytoma \[[@CR12],[@CR22]\]. In the present study, only three patients received radiation doses less than 40 Gy, and among these three patients, one patient experienced disease progression. In addition, the two patients who did not respond to initial radiotherapy received 42 Gy and 50 Gy of radiotherapy. These doses were similar to those administered to the patients who responded to treatment, and were hence considered sufficient; therefore, the doses of radiation may not be responsible for the poor clinical responses, when radiation over 40 Gy was given.

Since disease multiplicity is associated with a higher risk of systemic involvement and a high burden of clonal plasma cells, it represents a very important factor to take into account for the decision of the treatment, especially, for patients with an underlying OSM. As a result, these patients are usually treated with chemotherapy, and the role of radiotherapy is thus uncertain in these patients. In the present study, six patients with multiple lesions underwent radiotherapy, and this was found to have effectively improved the POEMS associated symptoms, although the hematologic response to radiotherapy was relatively poor in these patients.

Furthermore, in the present study, among the six patients presenting with VEGF elevation without gross lesions, five patients were treated with systemic chemotherapy, whereas the other one patient received systemic corticosteroid therapy and intravenous immunoglobulin. Interestingly, the treatment responses of these patients were poorer than those of the patients with osteosclerotic myeloma (Table [4](#Tab4){ref-type="table"}). Moreover, the PFS and OS rates were found to be significantly inferior in these patients compared to those in patients with other subtypes of underlying disease (Table [5](#Tab5){ref-type="table"}). A French study reported that six out of 25 POEMS patients did not have bone lesion-like monoclonal gammopathy of unknown significance \[[@CR23]\], and clinical improvement was observed in only one patient among four patients with available data in that series \[[@CR5]\]. The reason for the poor clinical outcomes in these patients is unclear, and previous studies have reported only a small number of POEMS patients presenting with VEGF elevation without gross lesions; therefore, further investigations regarding these patients is needed.

In the present study, the administration of chemotherapy significantly improved PFS and OS. Previous studies have demonstrated that melphalan-based chemotherapy protocols were able to achieve response rates over 40% \[[@CR4],[@CR6],[@CR15],[@CR24]\]. Moreover, high-dose chemotherapy with PBSCT has also produced encouraging results, with a 5-year PFS of 75% \[[@CR11],[@CR13],[@CR25],[@CR26]\]. Therefore, the selection of patients indicated for chemotherapy and the choice of chemotherapy regimen based on the patients' underlying clonal disease are important to improve outcomes.

The present study has some limitations including the retrospective nature and the relatively small sample size. Moreover, patients who did not undergo radiotherapy more frequently presented with adverse events such as ascites, pleural effusion, or pericardial effusion compared to patients treated with radiotherapy. Furthermore, among the 13 patients treated with radiotherapy, nine patients also underwent chemotherapy; and therefore, there is a possibility that the effects of radiotherapy may have been overestimated. However, despite these limitations, radiotherapy was found to produce good clinical responses in patients with a solitary lesion and clustered or limited multiple lesions, and radiotherapy may hence be effective as a definitive treatment in POEMS patients with localized OSM or as a palliative treatment to improve clinical symptoms in POEMS patients with clustered or limited multiple lesions.

Conclusions {#Sec11}
===========

We here have shown that radiotherapy produced good clinical and hematologic responses, especially in patients with an underlying OSM. Additionally, radiotherapy and chemotherapy appear to both be effective treatments for underlying plasma cell proliferative diseases. Furthermore, we also found that patients with POEMS syndrome presenting with VEGF elevation without gross lesions tend to have a poor prognosis. Further large-scale studies are needed in the future to improve the understanding of the underlying disease pathogenesis and to elucidate the appropriate management of this disease based on patient characteristics.
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